Brief: Bellus Health Announces Topline Results From Phase 2 Relief Trial Of Blu-5937 For Treatment Of Refractory Chronic Cough

BELLUS Health

06/07/2020 12:12

July 6 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES TOPLINE RESULTS FROM ITS PHASE 2
RELIEF
TRIAL OF BLU-5937 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH
    * BELLUS HEALTH INC - PRIMARY ENDPOINT OF PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY DID NOT REACH STATISTICAL
SIGNIFICANCE
    * BELLUS HEALTH INC - BLU-5937 WAS WELL TOLERATED WITH LOW
IMPACT
ON TASTE PERCEPTION; SAFETY PROFILE COMPARABLE TO PLACEBO
    * BELLUS HEALTH INC - PATIENT ENRICHMENT STRATEGY WITH
HIGHER
COUGH COUNT PATIENTS TO BE PURSUED IN ADAPTIVE PHASE 2B TRIAL
EXPECTED TO START IN Q4 2020
    * BELLUS HEALTH- CLINICALLY MEANINGFUL REDUCTIONS IN PLACEBO
ADJUSTED AWAKE COUGH FREQUENCY ACHIEVED IN PRE-SPECIFIED
ANALYSIS OF HIGH COUGH COUNT PATIENTS

Source text for Eikon:  ID:nBw6sPR25a 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))